Molecular Formula | C17H18N2O6 |
Molar Mass | 346.33 |
Density | 1.2109 (rough estimate) |
Melting Point | 171-175 °C |
Boling Point | 481.08°C (rough estimate) |
Flash Point | 226.1°C |
Solubility | DMSO: soluble;ethanol: soluble. Soluble in acetone, chloroform, ethyl acetate, soluble in hot methanol, insoluble in water. It is easy to deteriorate when exposed to light. |
Vapor Presure | 2.68E-08mmHg at 25°C |
Appearance | Yellow crystalline solid |
Color | yellow |
Merck | 14,6528 |
pKa | pKa -0.9/>13(DMF,t undefined) (Uncertain) |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions are not stable and must be used within one working day. |
Sensitive | Sensitive to light |
Refractive Index | 1.5486 (estimate) |
MDL | MFCD00057326 |
Physical and Chemical Properties | Appearance: yellow crystalline powder or needle-like crystal. Odorless and tasteless.
|
Use | For the treatment of various acute and chronic coronary insufficiency, angina and other diseases |
In vitro study | In cultured human coronary artery endothelial cells, Nifedipine significantly increased eNOS protein expression in a concentration-dependent manner. Nifedipine antagonizes L-type calcium channels throughout the cardiovascular system and also blocks Kv channels, which are members of the same supergene family. Nifedipine dose-dependently decreases [(3)H]-Thymidine Incorporation, total cellular protein content, and phosphorylated extracellular signal-regulated protein kinase (ERK) in vascular smooth muscle cells (VSMC) 1/2, the level of mitogen-activated protein kinase kinase (MEK)1/2, and the phosphorylation of pyk2. Nifedipine dose-dependently inhibited proliferating cell nuclear antigen (PCNA) levels in VSMC and balloon-injured thoracic aortic vascular VSMC. |
In vivo study | In rats, Nifedipine(3 mg/kg) slightly decreased the level of systolic and/or diastolic blood pressure or increased heart rate. In choroidal arteriolar smooth muscle, Nifedipine(1 μm) produced the greatest inhibition of the store-operating pathway. In injured rat mucosa, Nifedipine(20 and 40 mg/kg) significantly prevented hydrochloric acid plus ethanol-induced gastric mucosal damage and increased thiobarbituric acid-reactive substances. In rat ulcer mucosa, Nifedipine(20 and 40 mg/kg) dose-dependently promoted ulcer healing and inhibited the increase of thiobarbituric acid-reactive substances. |
Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 1 |
RTECS | US7975000 |
HS Code | 29333990 |
Hazard Class | IRRITANT |
Toxicity | LD50 in mice, rats (mg/kg): 494, 1022 orally; 4.2, 15.5 i.v. (Vater) |
Reference Show more | 1. Zheng Mei, Liu Fulei, Xue Jingwei, et al. Study on the drug interaction between Liuwei Dihuang Pill and nifedipine based on liver microsomes and fingerprints [J]. Journal of China Pharmaceutical University, 2018, 49(02):70-76. 2. Wei Wenzeng, Zhao Ningning, Lin Yingfeng, Wang Jin, Wang Gong. Cocktail probe method to evaluate the effect of alcohol extract from Antrodia camphorata on human CYP450 enzyme activity [J]. Science and Technology Wind, 2021(03):139-140. 3. Wei Wenzeng, Zhao Ningning, Lin Yingfeng, Wang Jin, Wang Gong. Cocktail probe method to evaluate the effect of alcohol extract from Antrodia camphorata on human CYP450 enzyme activity [J]. Science and technology wind, 2021(03):139-140. 4. Bi Y, Lv B, Li L, Lee RJ, Xie J, Qiu Z, Teng L. A Liposomal Formulation for Improving Solubility and Oral Bioavailability of Nifedipine. Molecules. 2020; 25(2):338. https://doi.org/10.3390/molecules25020338 5. [IF = 4.411] Ye Bi et al."A Liposomal Formulation for Improving Solubility and Oral Bioavailability of Nifedipine." Molecules. 2020 Jan;25(2):338 6. [IF = 5.811] Jiang XL et al."Hepatoprotective Effect of Oplopanax elatus Nakai Adventitious Roots Extract by Regulating CYP450 and PPAR Signaling Pathway .." Frontiers in Pharmacology. 2022 May;13:761618-761618 |